Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12003240 | 1.00 | DPP4 (0.47) | DPP4SLC1A2SLC1A1CYP2C19GRM2 | |
| SCHEMBL17729296 | 1.00 | DPP4 (0.47) | DPP4SLC1A2SLC1A1CYP2C19GRM2 | |
| SCHEMBL1531463 | 0.90 | — | — | |
| SCHEMBL412802 | 0.90 | — | — | |
| SCHEMBL412803 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL17423095 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL17423093 | 0.87 | — | — | |
| SCHEMBL342059 | 0.81 | DPP4 (0.46) | DPP4SLC1A2SLC1A1CYP2C19GRM2 | |
| SCHEMBL650638 | 0.81 | DPP4 (0.46) | DPP4SLC1A2SLC1A1CYP2C19GRM2 | |
| SCHEMBL7077492 | 0.81 | DPP4 (0.46) | DPP4SLC1A2SLC1A1CYP2C19GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | claimed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | claimed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | claimed |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-10138270-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | claimed |
| US-20180028594-A1 | PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR HARD TISSUE PAIN | CARA THERAPEUTICS, INC. (US) | 2018-02-01 | — | — | US | claimed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | claimed |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2016-12-29 | — | — | US | claimed |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | US | claimed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-7727963-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | claimed |
| EP-2079756-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | Cara Therapeutics, Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| EP-2064228-A2 | SYNTHETIC PEPTIDE AMIDES | Cara Therapeutics, Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | claimed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | DPP4 1812/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | DPP4 1812/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-10138270-B2 | Synthetic peptide amides | VIP, OPRK1, OPRL1 | DPP4 2115/4885SLC1A2 162/4885SLC1A1 151/4885 |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | DPP4 833/4885SLC1A2 232/4885SLC1A1 198/4885 |
| US-20180028594-A1 | PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR HARD TISSUE PAIN | OPRK1, OPRL1, OPRD1 | DPP4 1588/4885SLC1A2 253/4885SLC1A1 131/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | DPP4 918/4885SLC1A2 151/4885SLC1A1 176/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | DPP4 865/4885SLC1A2 144/4885SLC1A1 161/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | DPP4 2115/4885SLC1A2 162/4885SLC1A1 151/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | DPP4 2605/4885SLC1A2 290/4885SLC1A1 262/4885 |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | DPP4 2115/4885SLC1A2 162/4885SLC1A1 151/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | DPP4 1812/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | DPP4 1812/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | DPP4 833/4885SLC1A2 232/4885SLC1A1 198/4885 |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | DPP4 833/4885SLC1A2 232/4885SLC1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.